This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
Talk:PPAP: Difference between revisions
>LVirs1 new substance |
>David Hedlund {{Experience reports|erowid_experience_substance_label=}} |
||
| (19 intermediate revisions by 8 users not shown) | |||
| Line 1: | Line 1: | ||
{{SubstanceBox/PPAP}} | {{headerpanel|{{approval}}}} | ||
{{distinguish|(-)-R-PPAP}} | |||
'''(-)-1-Phenyl-2-propylaminopentane''' (also known as '''(-)-PPAP''' and '''N,α-dipropylphenethylamine''') is a [[stimulant]] of the [[substituted phenethylamine]] class and a derivative of [[Selegiline]].<ref>{{cite journal | title=The pharmacology of 1-phenyl-2-propylamino-pentane (PPAP), a deprenyl-derived new spectrum psychostimulant. |vauthors=Knoll J, Knoll B, Török Z, Timár J, Yasar S | journal=Archives internationales de Pharmacodynamie et de Thérapie | date=March–April 1992 | issue=316 | pages=5–29 | pmid=1356324}}</ref> It is mainly considered as a [[nootropic]] and [[research chemical]]. | {{SubstanceBox/PPAP}}'''(-)-1-Phenyl-2-propylaminopentane''' (also known as '''(-)-PPAP''' and '''N,α-dipropylphenethylamine''') is a [[psychoactive class::stimulant]] of the [[chemical class::substituted phenethylamine]] class and a derivative of [[Selegiline]].<ref>{{cite journal | title=The pharmacology of 1-phenyl-2-propylamino-pentane (PPAP), a deprenyl-derived new spectrum psychostimulant. |vauthors=Knoll J, Knoll B, Török Z, Timár J, Yasar S | journal=Archives internationales de Pharmacodynamie et de Thérapie | date=March–April 1992 | issue=316 | pages=5–29 | pmid=1356324}}</ref> It is mainly considered as a [[nootropic]] and [[research chemical]]. | ||
PPAP is classified as a [[Monoamine neurotransmitter|monoaminergic]] activity enhancer that stimulates the impulse propagation mediated transmitter release of the [[neurotransmitter]]s [[dopamine]], [[norepinephrine]] and [[serotonin]] in the brain. Unlike stimulants such as [[amphetamine]], which release a flood of monoamine neurotransmitters in an uncontrolled manner, PPAP instead only increases the amount of neurotransmitters that get released when a [[neuron]] is stimulated by receiving an impulse from a neighbouring neuron. Both amphetamine and (-)-PPAP promote the release of monoamines and deuteramines, however while amphetamine causes neurons to dump neurotransmitter stores into the [[synapse]] regardless of external input, PPAP does not influence the pattern of neurotransmitter release and instead releases a larger amount of neurotransmitters than normal.<ref>{{cite journal | url=http://www.sciencedirect.com/science/article/pii/0024320596000148 | title=(−)Deprenyl and (−)1-phenyl-2-propylaminopentane, [(−) PPAP] act primarily as potent stimulants of action potential — transmitter release coupling in the catecholaminergic neurons |author1=Joseph Knoll |author2=Ildikó Miklya |author3=Berta Knoll |author4=Raissa Markó |author5=Károly Kelemen | journal=Life Sciences | date=February 1996 | volume=58 | issue=10 | pages=817–827 | doi=10.1016/0024-3205(96)00014-8 | pmid=8602114}}</ref> | PPAP is classified as a [[Monoamine neurotransmitter|monoaminergic]] activity enhancer that stimulates the impulse propagation mediated transmitter release of the [[neurotransmitter]]s [[dopamine]], [[norepinephrine]] and [[serotonin]] in the brain. Unlike stimulants such as [[amphetamine]], which release a flood of monoamine neurotransmitters in an uncontrolled manner, PPAP instead only increases the amount of neurotransmitters that get released when a [[neuron]] is stimulated by receiving an impulse from a neighbouring neuron. Both amphetamine and (-)-PPAP promote the release of monoamines and deuteramines, however while amphetamine causes neurons to dump neurotransmitter stores into the [[synapse]] regardless of external input, PPAP does not influence the pattern of neurotransmitter release and instead releases a larger amount of neurotransmitters than normal.<ref>{{cite journal | url=http://www.sciencedirect.com/science/article/pii/0024320596000148 | title=(−)Deprenyl and (−)1-phenyl-2-propylaminopentane, [(−) PPAP] act primarily as potent stimulants of action potential — transmitter release coupling in the catecholaminergic neurons |author1=Joseph Knoll |author2=Ildikó Miklya |author3=Berta Knoll |author4=Raissa Markó |author5=Károly Kelemen | journal=Life Sciences | date=February 1996 | volume=58 | issue=10 | pages=817–827 | doi=10.1016/0024-3205(96)00014-8 | pmid=8602114}}</ref> | ||
| Line 8: | Line 8: | ||
==Subjective effects== | ==Subjective effects== | ||
In comparison to traditional stimulants such as [[amphetamine]], this compound induces an experience which is far less forceful, recreational and euphoric. Although in comparison to [[modafinil]] it is usually considered to be more mood-lifting and energetic. | In comparison to traditional stimulants such as [[amphetamine]], this compound induces an experience which is far less forceful, recreational and euphoric. Although in comparison to [[modafinil]] it is usually considered to be more mood-lifting and energetic. Unlike for most other stimulants, the | ||
expressiveness of PPAP effects are somehow dependent on [[set and setting]] due to it's unique pharmacological activity. | |||
{{Preamble/SubjectiveEffects}} | {{Preamble/SubjectiveEffects}} | ||
{{effects/base | {{effects/base | ||
|{{effects/physical| | |{{effects/physical| | ||
*'''[[Effect::Stimulation]]''' - In terms of its effects on the user's physical energy levels, PPAP is commonly considered to be stimulating and energetic, but can be considered as less stimulating when compared to [[amphetamine]] and [[methylphenidate]], but stronger than that of [[modafinil]] and [[caffeine]]. | *'''[[Effect::Stimulation]]''' - In terms of its effects on the user's physical energy levels, PPAP is commonly considered to be stimulating and energetic, but can be considered as less stimulating when compared to [[amphetamine]] and [[methylphenidate]], but similar or stronger than that of [[modafinil]] and [[caffeine]]. | ||
*'''[[Effect::Spontaneous physical sensations]]''' - The "body high" of PPAP is fairly pronounced even in moderate doses, although less intense than that of amphetamine. | |||
*'''[[Effect::Increased heart rate]]''' | *'''[[Effect::Increased heart rate]]''' | ||
*'''[[Effect::Dehydration]]''' - Dehydration and dry mouth commonly occur due to an increase in motivation to engage in physical activities as well as an increased sense of focus which causes one to forget to drink water. | *'''[[Effect::Dehydration]]''' - Dehydration and dry mouth commonly occur due to an increase in motivation to engage in physical activities as well as an increased sense of focus which causes one to forget to drink water. | ||
*'''[[Effect::Appetite suppression]]''' | *'''[[Effect::Appetite suppression]]''' | ||
*'''[[Effect::Increased perspiration]]''' | |||
*'''[[Effect::Dizziness]]''' | *'''[[Effect::Dizziness]]''' | ||
*'''[[Effect::Stamina enhancement]]''' | |||
*'''[[Effect::Irritability]]''' | *'''[[Effect::Irritability]]''' | ||
}} | }} | ||
{{effects/visual| | |||
*'''[[Effect::Acuity enhancement]]''' | |||
*'''[[Effect::Colour enhancement]]''' | |||
}} | |||
|{{effects/cognitive| | |{{effects/cognitive| | ||
*'''[[Effect::Anxiety]]''' or '''[[Effect::Anxiety suppression]]''' | *'''[[Effect::Anxiety]]''' or '''[[Effect::Anxiety suppression]]''' | ||
*'''[[Effect::Wakefulness]]''' | *'''[[Effect::Wakefulness]]''' | ||
*'''[[Effect::Cognitive euphoria]]''' | |||
*'''[[Effect::Motivation enhancement]]''' | *'''[[Effect::Motivation enhancement]]''' | ||
*'''[[Effect::Focus enhancement]]''' | *'''[[Effect::Focus enhancement]]''' | ||
| Line 35: | Line 44: | ||
}} | }} | ||
}} | }} | ||
===Experience reports=== | |||
{{Experience reports|erowid_experience_substance_label=}} | |||
==Toxicity and harm potential== | ==Toxicity and harm potential== | ||
The toxicity and long-term health effects of recreational PPAP use do not seem to have been studied in any scientific context and the [[Toxicity::exact toxic dosage is unknown]]. This is because PPAP has very little history of human usage. Anecdotal evidence from people who have tried PPAP within the community suggest that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed). | The toxicity and long-term health effects of recreational PPAP use do not seem to have been studied in any scientific context and the [[Toxicity::exact toxic dosage is unknown]]. This is because PPAP has very little history of human usage. Anecdotal evidence from people who have tried PPAP within the community suggest that there do not seem to be any negative health effects attributed to simply trying this drug at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed). | ||
The | The LD<sub>50</sub> of PPAP in rats is 270 mg/kg p.o.<ref name="Knoll" /> | ||
It is strongly recommended that one use [[responsible drug use|harm reduction practices]] when using this drug. | It is strongly recommended that one use [[responsible drug use|harm reduction practices]] when using this drug. | ||
| Line 51: | Line 62: | ||
{{DangerousInteractions/Intro}} | {{DangerousInteractions/Intro}} | ||
{{DangerousInteractions/Stimulants|self=PPAP}} | {{DangerousInteractions/Stimulants|self=PPAP}} | ||
{{DangerousInteractions/MAOI|nt=dopamine}} | {{DangerousInteractions/MAOI|nt=dopamine}} | ||
*'''[[DangerousInteraction::MDMA]]''' - The neurotoxic effects of [[MDMA]] may be increased when combined with other stimulants. | *'''[[DangerousInteraction::MDMA]]''' - The neurotoxic effects of [[MDMA]] may be increased when combined with other stimulants. | ||
==Legal status== | ==Legal status== | ||
{{LegalStub}} | |||
*'''United States''': PPAP has no schedule assigned to it in the U.S., making it unregulated and therefore legally available for anyone in the country to buy, possess and use. | *'''United States''': PPAP has no schedule assigned to it in the U.S., making it unregulated and therefore legally available for anyone in the country to buy, possess and use. | ||
*'''United Kingdom:''' It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016.<ref>Psychoactive Substances Act 2016 (Legislation.gov.uk) | http://www.legislation.gov.uk/ukpga/2016/2/contents/enacted</ref> | *'''United Kingdom:''' It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016.<ref>Psychoactive Substances Act 2016 (Legislation.gov.uk) | http://www.legislation.gov.uk/ukpga/2016/2/contents/enacted</ref> | ||
==See also== | ==See also== | ||
*[[Responsible use]] | *[[Responsible use]] | ||
*[[Nootropics]] | *[[Nootropics]] | ||
| Line 66: | Line 80: | ||
==External links== | ==External links== | ||
*[https://en.wikipedia.org/wiki/Phenylpropylaminopentane Phenylpropylaminopentane (Wikipedia)] | *[https://en.wikipedia.org/wiki/Phenylpropylaminopentane Phenylpropylaminopentane (Wikipedia)] | ||
*[https://isomerdesign.com/PiHKAL/explore.php?id=10771 1-Phenyl-2-propylaminopentane (TiHKAL / Isomer Design)] | |||
==References== | ==References== | ||
| Line 72: | Line 88: | ||
[[Category:Psychoactive substance]] | [[Category:Psychoactive substance]] | ||
[[Category: | [[Category:Phenethylamine]] | ||
[[Category:Nootropic]] | [[Category:Nootropic]] | ||
[[Category:Stimulant]] | [[Category:Stimulant]] | ||
{{#set:Featured=true}} | {{#set:Featured=true}} | ||